Literature DB >> 8312942

Overview of the current status of total androgen deprivation in metastasized prostate cancer.

F M Debruyne1, W P Witjes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8312942     DOI： 10.1007/bf00185076

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  16 in total

1.  Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?

Authors:  F Samdal; K Vada; P I Lundmo; O K Mjølnerød
Journal:  Scand J Urol Nephrol       Date:  1991

2.  Cancer statistics, 1991.

Authors:  C C Boring; T S Squires; T Tong
Journal:  CA Cancer J Clin       Date:  1991 Jan-Feb       Impact factor: 508.702

3.  How would you like to have an orchidectomy for advanced prostatic cancer?

Authors:  H Parmar; R H Phillips; S L Lightman; L Edwards
Journal:  Am J Clin Oncol       Date:  1988       Impact factor: 2.339

4.  Cancer in the European Community and its member states.

Authors:  O M Jensen; J Estève; H Møller; H Renard
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

6.  Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer.

Authors:  J Geller; D J de la Vega; J D Albert; D A Nachtsheim
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

7.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

Authors:  F Labrie; A Dupont; A Belanger; L Cusan; Y Lacourciere; G Monfette; J G Laberge; J P Emond; A T Fazekas; J P Raynaud; J M Husson
Journal:  Clin Invest Med       Date:  1982       Impact factor: 0.825

8.  Total androgen ablation: European experience. The EORTC GU Group.

Authors:  L Denis; P Smith; J L Carneiro de Moura; D Newling; A Bono; F Keuppens; C Mahler; M Robinson; R Sylvester; M De Pauw
Journal:  Urol Clin North Am       Date:  1991-02       Impact factor: 2.241

Review 9.  Hormone therapy of advanced prostate cancer: where we stand today.

Authors:  E D Crawford; W Nabors
Journal:  Oncology (Williston Park)       Date:  1991-01       Impact factor: 2.990

10.  Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.

Authors:  P Henriksson; S E Johansson
Journal:  Am J Epidemiol       Date:  1987-06       Impact factor: 4.897
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.